Navigation Links
OncoGenex Reports Second Quarter Financial Results
Date:8/5/2010

with advanced prostate cancer, many patients will eventually develop treatment resistance and their disease will progress."

Cormack added, "Our partnership with Teva Pharmaceuticals has financed a robust clinical trial program for custirsen and provided us with the cash to fund operations into mid-2012, while retaining royalty rates which we estimate at the higher tiers could approach economics seen in profit-sharing arrangements. We're now focusing on advancing OGX-427 to more fully realize its diverse potential. We are currently evaluating various alternatives, including partnering, which would allow us to expand the OGX-427 development plan beyond the ongoing Phase 1 bladder cancer trial and the randomized Phase 2 prostate cancer trial planned to initiate later this year."

Recent Accomplishments and Anticipated Milestones

    Custirsen
    ---------

      -  In partnership with Teva, we initiated the international Phase 3
         Prostate Cancer SATURN trial evaluating custirsen with docetaxel
         retreatment as second-line therapy in castrate-resistant prostate
         cancer (CRPC). The SATURN trial will be conducted in approximately
         50 cancer centers and will enroll approximately 300 men who have
         previously responded to first-line docetaxel therapy, but
         subsequently have disease progression that involves prostate cancer-
         related pain despite opioid usage.

      -  Two additional Phase 3 trials will be initiated evaluating custirsen
         in first-line treatment of metastatic CRPC and first-line treatment
         of advanced, unresectable non-small cell lung cancer (NSCLC). Both
         trials will be in combination with chemotherapy and will assess
         overall survival as the primary endpoint.

    OGX-427
    -------

      -  Final results from a Phase 1 trial of OGX-427 were announced at the
         ASCO 2010 Annual Meetin
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
3. OncoGenex Reports First Quarter Financial Results
4. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
5. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
6. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
7. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
8. OncoGenex Reports Third Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
11. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic Biologics, ... developing novel anti-infective biologic and drug programs targeting ... announced today that its novel C. difficile ... 54 th Interscience Conference on Antimicrobial Agents ... Washington D.C. Synthetic Biologics, ...
(Date:8/19/2014)... Sales Horizons, a leader in sales training, ... skills training course to help companies develop clinical ... spend the majority of their time on client sites ... physician practice – providing support and education to both ... Horizons believes clinical staff are and should be considered ...
(Date:8/18/2014)... new therapy developed by researchers at the University ... and Columbia University Medical Center (CUMC) may help ... treatment. , The researchers demonstrated in a ... selectively inhibit blood vessel re-narrowing and simultaneously promote ... balloon catheter to open narrowed or blocked arteries. ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3
... July 19, 2010 -- Tomorrow,s television and computer screens ... result of a process developed by a team of ... Ridge National Laboratory. The synthesis of a conjugated ... like light-emitting diodes, televisions and solar cells--could mean more ...
... announces that a new market research report is available in its catalogue: , ... Outlook to 2016 , , , ... China In Vitro Diagnostics Market Outlook to 2016 , ... Summary , , , ...
... N.Y. , July 19 On June ... Senator Charles Grassley released a report entitled "Ghostwriting ... transparency that exists in medical ghostwriting." The report rightly calls ... medical publications and more specificity in acknowledging editorial assistance. However, ...
Cached Biology Technology:Polymer synthesis could aid future electronics 2Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 2Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 3Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 4Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 5Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 6Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 7Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 8Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 9Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 10Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 11Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 12Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 13Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 14Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 15Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 16Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 17Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 18Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 19Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 20Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 21Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 22Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 23Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 24Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 25Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 26ISMPP Reiterates Progress in Medical Publications in Response to Senator Grassley's Report 2ISMPP Reiterates Progress in Medical Publications in Response to Senator Grassley's Report 3
(Date:8/19/2014)... Research and Network-Level Science, , Imagine if we had ... ecosystems was responding to global changes in real time. ... coupled multiple decades of information about ecological responses to ... dozens of different ecosystem types. , In fact, ... (LTER) Network, which will soon celebrate its 35th anniversary. ...
(Date:8/19/2014)... engineers have devised a new implantable tissue scaffold coated ... a few weeks. When applied to bone injuries or ... form new bone that looks and behaves just like ... could offer a dramatic improvement over the current standard ... another part of the patient,s body a painful ...
(Date:8/19/2014)... today,s crocodiles colonised the seas during warm phases and ... Anglo-French study which establishes a link between marine crocodilian ... period of more than 140 million years. , ... Universit de Lyon, France and formerly from the University ... Nature Communications ., Today, crocodiles are ,cold-blooded, animals that ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2Engineering new bone growth 2Engineering new bone growth 3Evolution of marine crocodilians constrained by ocean temperatures 2
... of fossils locked inside rocks may flip the order in ... to have moved from fish to landlubber. Both extinct ... million years ago in what is now Greenland. Acanthostega was ... the first vertebrate animal to possess limbs with digits rather ...
... Germany,s Federal Minister for Food, Agriculture and Consumer ... genetically modified maize. The ban took effect immediately ... ban is an isolated decision on a particular ... engineering. Europe,s highest licensing authority, the EFSA, had ...
... The Office of Naval Research (ONR) has announced ... Navy,s 2009 Young Investigator Program (YIP). "We ... minds in science, technology, engineering and mathematics," says Chief ... in initiatives like the Young Investigator Program, ONR is ...
Cached Biology News:Fossils suggest earlier land-water transition of tetrapod 2Fossils suggest earlier land-water transition of tetrapod 3Joint statement by German science organizations on green genetic engineering 2ONR announces 2009 Young Investigator Award recipients 2
BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... low background fluorescence, minimal light scatter ... medium binding) polystyrene surface is hydrophobic ... passive interactions,• Is suitable primarily ... such as antibodies, that have large ...
... microplate washer, 100-240 V, is used for ... or V-bottom wells. This washer has programmability ... an accuracy of 0.1 mm for bottom ... can store up to 75 wash sequences ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
Biology Products: